"Novo Nordisk's Weight Loss Trial Results Boost Shares, Eli Lilly Sees Dip"

Novo Nordisk's shares surged 8% to a record high after reporting positive early trial data for its experimental weight loss drug amycretin, showing a 13.1% weight loss in participants after 12 weeks, surpassing the results of its popular obesity drug Wegovy. The company's stock has risen over 27% this year due to high demand for its anti-obesity drugs. Additionally, late-stage trial results for Ozempic demonstrated its potential to reduce the risk of kidney disease progression and death, further strengthening Novo's position in the pharmaceutical market. Meanwhile, American rival Eli Lilly's shares dipped 0.6% in premarket trading in response to the news.